Dr. Pedro M. Barata
Claim this profileTulane University Health Sciences Center
Studies Cancer
Studies Renal Cell Carcinoma
20 reported clinical trials
52 drugs studied
Area of expertise
1Cancer
Stage IV
PD-L1 positive
Stage III
2Renal Cell Carcinoma
Stage IV
Stage III
TFE-3/B translocation positive
Affiliated Hospitals
Clinical Trials Pedro M. Barata is currently running
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting1 award Phase 221 criteria
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
More about Pedro M. Barata
Clinical Trial Related4 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Pedro M. Barata has experience with
- Ipilimumab
- Nivolumab
- Cabozantinib
- Pembrolizumab
- Lenvatinib
- Prednisone
Breakdown of trials Pedro M. Barata has run
Cancer
Renal Cell Carcinoma
Prostate Cancer
Kidney Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Pedro M. Barata specialize in?
Pedro M. Barata focuses on Cancer and Renal Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Pedro M. Barata currently recruiting for clinical trials?
Yes, Pedro M. Barata is currently recruiting for 9 clinical trials in New Orleans Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Pedro M. Barata has studied deeply?
Yes, Pedro M. Barata has studied treatments such as Ipilimumab, Nivolumab, Cabozantinib.
What is the best way to schedule an appointment with Pedro M. Barata?
Apply for one of the trials that Pedro M. Barata is conducting.
What is the office address of Pedro M. Barata?
The office of Pedro M. Barata is located at: Tulane University Health Sciences Center, New Orleans, Louisiana 70112 United States. This is the address for their practice at the Tulane University Health Sciences Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.